309 related articles for article (PubMed ID: 30995715)
21. LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro.
Xiao P; Sun LL; Wang J; Han RL; Ma Q; Zhong DS
Acta Pharmacol Sin; 2015 Sep; 36(9):1107-12. PubMed ID: 26027660
[TBL] [Abstract][Full Text] [Related]
22. LKB1 kinase-dependent and -independent defects disrupt polarity and adhesion signaling to drive collagen remodeling during invasion.
Konen J; Wilkinson S; Lee B; Fu H; Zhou W; Jiang Y; Marcus AI
Mol Biol Cell; 2016 Apr; 27(7):1069-84. PubMed ID: 26864623
[TBL] [Abstract][Full Text] [Related]
23. Deletion of endothelial cell-specific liver kinase B1 increases angiogenesis and tumor growth via vascular endothelial growth factor.
Zhang W; Ding Y; Zhang C; Lu Q; Liu Z; Coughlan K; Okon I; Zou MH
Oncogene; 2017 Jul; 36(30):4277-4287. PubMed ID: 28346429
[TBL] [Abstract][Full Text] [Related]
24. Reduced expression of liver kinase B1 and Beclin1 is associated with the poor survival of patients with non-small cell lung cancer.
Jiang L; Liang X; Liu M; Wang W; Ma J; Guo Q; Han L; Yang C; Nan K
Oncol Rep; 2014 Nov; 32(5):1931-8. PubMed ID: 25175672
[TBL] [Abstract][Full Text] [Related]
25. Implications of MDSCs-targeting in lung cancer chemo-immunotherapeutics.
Adah D; Hussain M; Qin L; Qin L; Zhang J; Chen X
Pharmacol Res; 2016 Aug; 110():25-34. PubMed ID: 27157248
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathologic correlations of liver kinase B1, E-cadherin, and N-cadherin expression in non-small cell lung cancer.
Liu S; Miao Y; Fan C; Liu Y; Yu J; Zhang Y; Dai S; Wang E
Appl Immunohistochem Mol Morphol; 2013 Jul; 21(4):334-40. PubMed ID: 23235348
[TBL] [Abstract][Full Text] [Related]
27. LKB1 loss by alteration of the NKX2-1/p53 pathway promotes tumor malignancy and predicts poor survival and relapse in lung adenocarcinomas.
Tsai LH; Chen PM; Cheng YW; Chen CY; Sheu GT; Wu TC; Lee H
Oncogene; 2014 Jul; 33(29):3851-60. PubMed ID: 23995788
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic Targeting of Vasculature in the Premetastatic and Metastatic Niches Reduces Lung Metastasis.
Ghouse SM; Vadrevu SK; Manne S; Reese B; Patel J; Patel B; Silwal A; Lodhi N; Paterson Y; Srivastava SK; Karbowniczek M; Markiewski MM
J Immunol; 2020 Feb; 204(4):990-1000. PubMed ID: 31900334
[TBL] [Abstract][Full Text] [Related]
29. Role of mTOR Signaling in Tumor Microenvironment: An Overview.
Conciatori F; Bazzichetto C; Falcone I; Pilotto S; Bria E; Cognetti F; Milella M; Ciuffreda L
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30126252
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.
Zheng H; Zeltsman M; Zauderer MG; Eguchi T; Vaghjiani RG; Adusumilli PS
Immunotherapy; 2017 Sep; 9(11):913-927. PubMed ID: 29338609
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
[TBL] [Abstract][Full Text] [Related]
32. Utilization of liquid chromatography mass spectrometry analyses to identify LKB1-APC interaction in modulating Wnt/β-catenin pathway of lung cancer cells.
Jian SF; Hsiao CC; Chen SY; Weng CC; Kuo TL; Wu DC; Hung WC; Cheng KH
Mol Cancer Res; 2014 Apr; 12(4):622-35. PubMed ID: 24448687
[TBL] [Abstract][Full Text] [Related]
33. Involvement of LKB1 in epithelial-mesenchymal transition (EMT) of human lung cancer cells.
Roy BC; Kohno T; Iwakawa R; Moriguchi T; Kiyono T; Morishita K; Sanchez-Cespedes M; Akiyama T; Yokota J
Lung Cancer; 2010 Nov; 70(2):136-45. PubMed ID: 20207041
[TBL] [Abstract][Full Text] [Related]
34. Liver kinase B1 suppresses growth of lung cancer cells through sonic hedgehog signaling pathway.
Song K; Zheng G; Zhao Y
Cell Biol Int; 2018 Aug; 42(8):994-1005. PubMed ID: 29573522
[TBL] [Abstract][Full Text] [Related]
35. LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment.
Peña CG; Nakada Y; Saatcioglu HD; Aloisio GM; Cuevas I; Zhang S; Miller DS; Lea JS; Wong KK; DeBerardinis RJ; Amelio AL; Brekken RA; Castrillon DH
J Clin Invest; 2015 Nov; 125(11):4063-76. PubMed ID: 26413869
[TBL] [Abstract][Full Text] [Related]
36. WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.
Richer AL; Cala JM; O'Brien K; Carson VM; Inge LJ; Whitsett TG
Cancer Res; 2017 Sep; 77(17):4663-4672. PubMed ID: 28652249
[TBL] [Abstract][Full Text] [Related]
37. LKB1/AMPK/mTOR signaling pathway in non-small-cell lung cancer.
Han D; Li SJ; Zhu YT; Liu L; Li MX
Asian Pac J Cancer Prev; 2013; 14(7):4033-9. PubMed ID: 23991948
[TBL] [Abstract][Full Text] [Related]
38. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
39. CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy.
Bai X; Guo ZQ; Zhang YP; Fan ZZ; Liu LJ; Liu L; Long LL; Ma SC; Wang J; Fang Y; Tang XR; Zeng YJ; Pan X; Wu DH; Dong ZY
Nat Commun; 2023 Mar; 14(1):1247. PubMed ID: 36871040
[TBL] [Abstract][Full Text] [Related]
40. Bridging angiogenesis and immune evasion in the hypoxic tumor microenvironment.
Schito L
Am J Physiol Regul Integr Comp Physiol; 2018 Dec; 315(6):R1072-R1084. PubMed ID: 30183339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
